LYELL IMMUNOPHARMA, INC.

Analyst Reco. Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
1.45 ^USD	+5.07%		-29.27%	-25.26%

06-27	HC Wainwright Downgrades Lyell Immunopharma to Neutral From Buy, Slashes Price Target to $1 From $6	MT
06-26	Lyell Immunopharma Reports Dose-Dependent Clinical Activity from Phase 1 Trial of Lyl797, A Ror1-Targeted Car-T Cell Product Candidate Enhanced with Its Proprietary Anti-Exhaustion Technology	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Lyell Immunopharma to Neutral From Buy, Slashes Price Target to $1 From $6	06-27	MT
HC Wainwright Trims Lyell Immunopharma's Price Target to $8 From $9, Maintains Buy Rating	11-09	MT
JPMorgan Downgrades Lyell Immunopharma to Neutral From Overweight, Adjusts Price Target to $5 From $15	28/08/23	MT
HC Wainwright Adjusts Price Target on Lyell Immunopharma to $9 From $11, Maintains Buy Rating	02/03/23	MT
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $4 From $7, Maintains Equal Weight Rating	24/01/23	MT
Morgan Stanley Downgrades Lyell Immunopharma to Equalweight From Overweight, Adjusts Price Target to $7 From $15	14/11/22	MT
HC Wainwright Starts Lyell Immunopharma at Buy With $12 Price Target	17/10/22	MT
Goldman Sachs Adjusts Price Target for Lyell Immunopharma to $12 From $21, Keeps Buy Rating	24/05/22	MT
JPMorgan Lowers Price Target for Lyell Immunopharma to $15 From $22, Maintains Overweight Rating	31/03/22	MT
Goldman Sachs Adjusts Lyell Immunopharma Price Target to $21 From $31, Maintains Buy Rating	31/03/22	MT
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $20 from $25, Keeps Overweight Rating	06/01/22	MT
LYELL IMMUNOPHARMA : JPMorgan Starts Lyell Immunopharma at Overweight With $22 Price Target	12/07/21	MT
LYELL IMMUNOPHARMA : Morgan Stanley Starts Lyell Immunopharma at Overweight With $25 Price Target	12/07/21	MT
LYELL IMMUNOPHARMA : BofA Securities Starts Lyell Immunopharma at Buy With $25 Price Target	12/07/21	MT
LYELL IMMUNOPHARMA : Goldman Sachs Starts Lyell Immunopharma at Buy With $30 Price Target	12/07/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer